trial
as of 2026-07-01Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
NCTId NCT05184335
at a glance
Phase 3 · Recruiting
Enrollment 690 (estimated)
Sponsored by Reviva Pharmaceuticals
Primary completion 2025-02
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Recruiting
Enrollment
690 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2022-01-24
Primary completion
2025-02
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Drugs
Indications
Sponsors
Reviva PharmaceuticalsLead Sponsor
Sites
18 total
Phoenix, United StatesBentonville, United StatesLittle Rock, United StatesRogers, United StatesGarden Grove, United StatesLemon Grove, United StatesRiverside, United StatesHollywood, United StatesHollywood, United StatesMiami Lakes, United StatesAtlanta, United StatesDecatur, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
690
Phase
PHASE3
Primary Completion Date
2025-02
Status
RECRUITING
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
indication
indication